Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Refractory Malignant Female Reproductive System Neoplasm”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Early research (Phase 1)Looking for participantsNCT04840589
What this trial is testing

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 66
Early research (Phase 1)Active Not RecruitingNCT02298959
What this trial is testing

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Malignant Solid Neoplasm+12 more
National Cancer Institute (NCI) 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT03610490
What this trial is testing

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Who this might be right for
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395079
What this trial is testing

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Who this might be right for
Metastatic Malignant Female Reproductive System NeoplasmPlatinum-Resistant Malignant Female Reproductive System NeoplasmRecurrent Malignant Female Reproductive System Neoplasm+1 more
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Study completedNCT03508570
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Who this might be right for
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
M.D. Anderson Cancer Center 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
9